Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Other Operating Expenses (2016 - 2025)

ImmunityBio (IBRX) has disclosed Other Operating Expenses for 10 consecutive years, with $103.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 202.66% to $103.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $332.6 million, a 143.66% increase, with the full-year FY2025 number at $369.3 million, up 97.66% from a year prior.
  • Other Operating Expenses was $103.0 million for Q4 2025 at ImmunityBio, up from $51.4 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $182.0 million in Q4 2023 to a low of $27.9 million in Q4 2021.
  • A 5-year average of $65.0 million and a median of $54.1 million in 2022 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: surged 209.81% in 2023, then crashed 81.31% in 2024.
  • ImmunityBio's Other Operating Expenses stood at $27.9 million in 2021, then surged by 110.52% to $58.8 million in 2022, then soared by 209.81% to $182.0 million in 2023, then tumbled by 81.31% to $34.0 million in 2024, then surged by 202.66% to $103.0 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Other Operating Expenses are $103.0 million (Q4 2025), $51.4 million (Q3 2025), and $97.7 million (Q2 2025).